Taking into account that only patients harboring at least 15% of rearranged cells in FISH analysis show benefit from ALK-TKIs treatment [8, 9], the utility of RT-PCR assays in qualification of NSCLC patients for targeted therapy appears to be insufficient [11]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.